OncoSec enters collaboration with Dana-Farber Cancer Institute
OncoSec Medical announced that it has entered into a collaboration with Dana-Farber Cancer Institute, and The Marasco Laboratory, a cutting-edge CAR T-cell research laboratory led by Wayne Marasco, M.D., Ph.D., a renowned cancer immunology researcher, to develop CAR T-cell therapies for triple-negative breast cancer and other solid tumor cancers. Under the terms of the agreement, OncoSec has acquired an exclusive option to licensing rights to the CAR T-cell product candidates and associated IP resulting from the research being conducted at The Marasco Laboratory using engineered single-chain variable fragment antibodies in a dual-targeted bi-specific CAR T-cell approach. Previous research conducted by The Marasco Laboratory suggests their proprietary CAR T-cell technology has the potential to be effective against numerous solid tumor indications, while minimizing the toxicity that current CAR T-cell technologies exhibit when applied beyond liquid tumor indications. The company plans to begin clinical trials with the TNBC CAR T-cell therapy in 2020, both as a monotherapy and in combination with OncoSec's TAVO.